371 related articles for article (PubMed ID: 29117395)
1. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
[No Abstract] [Full Text] [Related]
2. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
3. Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy.
Eaglstein WH
JAMA Dermatol; 2016 Feb; 152(2):139-40. PubMed ID: 26606648
[No Abstract] [Full Text] [Related]
4. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
Bach PB; Giralt SA; Saltz LB
JAMA; 2017 Nov; 318(19):1861-1862. PubMed ID: 28975266
[No Abstract] [Full Text] [Related]
5. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
7. How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
Cooper S; Bouvy JC; Baker L; Maignen F; Jonsson P; Clark P; Palmer S; Boysen M; Crabb N
BMJ; 2020 Jan; 368():l6435. PubMed ID: 31896539
[No Abstract] [Full Text] [Related]
8. Tackling Cost: A Prescription for Spending Wisely.
Tempero M
J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
[No Abstract] [Full Text] [Related]
9. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
10. NICE, the NHS, and Cancer Drugs.
Dillon A; Landells LJ
JAMA; 2018 Feb; 319(8):767-768. PubMed ID: 29387883
[No Abstract] [Full Text] [Related]
11. Pharmacoeconomic analyses make way into oncology.
Amber D
J Natl Cancer Inst; 2000 Aug; 92(15):1204-5. PubMed ID: 10922402
[No Abstract] [Full Text] [Related]
12. Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
Becker DJ; Lin D; Lee S; Levy BP; Makarov DV; Gold HT; Sherman S
J Oncol Pract; 2017 Jul; 13(7):e653-e665. PubMed ID: 28493760
[TBL] [Abstract][Full Text] [Related]
13. Oncology drugs enter the US market faster than in Europe but cost more.
Mitka M
JAMA; 2012 Aug; 308(6):555. PubMed ID: 22871850
[No Abstract] [Full Text] [Related]
14. Paying for Cancer Drugs That Prove Their Benefit.
Frank RG; Emanuel EJ
JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
[No Abstract] [Full Text] [Related]
15. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
[TBL] [Abstract][Full Text] [Related]
16. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
Mailankody S; Prasad V
JAMA Oncol; 2015 Jul; 1(4):539-40. PubMed ID: 26181265
[No Abstract] [Full Text] [Related]
17. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.
Jiang DM; Chan KKW; Jang RW; Booth C; Liu G; Amir E; Mason R; Everest L; Elimova E
Cancer Med; 2019 Apr; 8(4):1584-1593. PubMed ID: 30848108
[TBL] [Abstract][Full Text] [Related]
18. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
Sobrero A; Bruzzi P
J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
[No Abstract] [Full Text] [Related]
19. Cost of Cancer Drugs: Something Has To Give.
Bender E
Manag Care; 2018 May; 27(5):18-22. PubMed ID: 29763403
[TBL] [Abstract][Full Text] [Related]
20. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Prasad V; Mailankody S
Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
